TriSalus Life Sciences, Inc.

NASDAQ:TLSI

Medical - Devices

Healthcare
$2.45 +0.49%

+$0.02 today

Market cap
$151.16M
Beta
0.49
P/E (TTM)
-7.4
EPS (TTM)
-$0.53
52W Low $2.20High $7.95

Volume 0.40M

Average 0.38M

TLSI Common Stock Repurchased

Cash spent buying back the company's own shares.

TriSalus Life Sciences, Inc.NASDAQ: TLSI

Common Stock Repurchased · Q1 FY2026 · quarter ended Mar 2026

Common stock repurchased outflow grows to $0

Q1 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was $0.

Context

  • Common stock repurchased amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Common stock repurchased increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Common Stock Repurchased vs competitors

How TLSI compares with its peers on the latest reported figures

  • TLSI's LTM Mar 2026 common stock repurchased of $0 is the 3rd largest of the 11 companies compared; the peer median is $0.
  • Common stock repurchased amounts to 0.0% of revenue for TLSI, versus a peer median of 0.0%.
TLSI Competitors Peer median
Common Stock Repurchased for TLSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PREPrenetics Global LimitedLTM Mar 2026$13.12M ——11.5%
AVRAnteris Technologies Global Corp.LTM Mar 2026$97K ——5.2%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$0 ——0.0%
PROFProfound Medical Corp.LTM Mar 2026$0 ——0.0%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$0 +100.0%—0.0%
MXCTMaxCyte, Inc.LTM Mar 2026$0 ——0.0%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
STIMNeuronetics, Inc.LTM Mar 2026$0 ——0.0%
OWLTOwlet, Inc.LTM Mar 2026$0 ——0.0%
LNSRLENSAR, Inc.LTM Mar 2026$0 ——0.0%
NNOXNano-X Imaging Ltd.LTM Dec 2025$0 ——0.0%
Peer median (excluding TLSI) $0+100.0%—0.0%

Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(28.85M)(47.19M)(59.36M)(30.05M)(39.23M)
Depreciation & Amortization464K398K684K744K626K
Deferred Income Tax00000
Stock-Based Compensation109K368K1.4M5.44M9.13M
Change in Working Capital(131K)2.3M537K(9.55M)2.07M
Accounts Receivables(741K)(200K)(1.98M)(1.72M)(1.63M)
Inventory(725K)(179K)(1.07M)(1.5M)971K
Accounts Payables3.18M5.25M2.84M(4.38M)2.02M
Other Working Capital(1.84M)(2.57M)751K(1.94M)711K
Other Non-Cash Items5.71M11.81M6.16M(7.43M)9.39M
Operating Cash Flow(22.7M)(32.31M)(50.58M)(40.84M)(18.01M)
Capital Expenditures(1.26M)(786K)(588K)(345K)(918K)
Acquisitions (Net)000080K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(1.16M)(1.13M)(1M)00
Investing Cash Flow(2.26M)(1.79M)(1.59M)(345K)(838K)
Debt Repayment(1.3M)(131K)(87K)24.92M9.92M
Common Stock Issued00015.54M22.91M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities54K94K45.53M(2.52M)(2.07M)
Financing Cash Flow50.77M13.46M54.63M37.94M30.76M
Effect of Forex Changes00000
Net Change in Cash25.81M(20.64M)2.46M(3.25M)11.91M
Free Cash Flow(23.96M)(33.1M)(51.17M)(41.19M)(18.93M)

TriSalus Life Sciences, Inc.

NASDAQ:TLSI

Intrinsic Alpha fair value

Locked

Current Price

$2.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.